PRIMECAP MANAGEMENT CO/CA/
Institutional investor · Portfolio as of Q3 2023
Top Holdings331 positions
Eli Lilly & Co. | 23.1M | $12.4B | 10.5% | $104.89 | +401.65% | 20 qtrssince 2018-Q4 | Decreased 0 |
BIOGEN INC | 16M | $4.1B | 3.5% | $298.84 | -14.00% | 20 qtrssince 2018-Q4 | Decreased 0 |
Amgen Inc. | 14.7M | $4B | 3.3% | $154.26 | +59.25% | 20 qtrssince 2018-Q4 | Decreased 0 |
FEDEX CORP | 13.1M | $3.5B | 2.9% | $117.29 | +71.38% | 20 qtrssince 2018-Q4 | Decreased 0 |
Microsoft Corp. | 10.5M | $3.3B | 2.8% | $94.43 | +226.71% | 20 qtrssince 2018-Q4 | Decreased 0 |
Adobe Inc | 6M | $3.1B | 2.6% | $226.24 | +125.38% | 20 qtrssince 2018-Q4 | Decreased 0 |
ASTRAZENECA PLC | 43.9M | $3B | 2.5% | $62.66 | +106.35% | 20 qtrssince 2018-Q4 | Decreased 0 |
KLA Corp. | 6M | $2.8B | 2.3% | $8.13 | +451.16% | 20 qtrssince 2018-Q4 | Decreased 0 |
INTEL CORP | 74.8M | $2.7B | 2.2% | $38.49 | -9.17% | 20 qtrssince 2018-Q4 | Increased 58 |
Micron Technology Inc. | 37.6M | $2.6B | 2.2% | $30.95 | +117.40% | 20 qtrssince 2018-Q4 | Decreased 0 |
Alphabet Inc. | 19.4M | $2.5B | 2.1% | $52.04 | +149.10% | 20 qtrssince 2018-Q4 | Decreased 0 |
Texas Instruments Inc. | 15.8M | $2.5B | 2.1% | $76.19 | +91.54% | 20 qtrssince 2018-Q4 | Decreased 0 |
Tesla Inc | 9.1M | $2.3B | 1.9% | $19.31 | +1195.70% | 20 qtrssince 2018-Q4 | Decreased 0 |
Boston Scientific Corporation | 37.4M | $2B | 1.7% | $35.74 | +47.75% | 20 qtrssince 2018-Q4 | Decreased 0 |
SONY CORP | 22.7M | $1.9B | 1.6% | $9.26 | +76.26% | 20 qtrssince 2018-Q4 | Decreased 0 |
WELLS FARGO CO NEW | 43.7M | $1.8B | 1.5% | $36.98 | +2.74% | 20 qtrssince 2018-Q4 | Decreased 0 |
Alphabet Inc. | 12.9M | $1.7B | 1.4% | $51.29 | +154.63% | 20 qtrssince 2018-Q4 | Decreased 0 |
BIOMARIN PHARMACEUTICAL INC | 18.4M | $1.6B | 1.4% | $84.70 | +4.47% | 20 qtrssince 2018-Q4 | Increased 50 |
SPLUNK INC | 11.1M | $1.6B | 1.4% | — | — | 20 qtrssince 2018-Q4 | Decreased 0 |
Thermo Fisher Scientific Inc | 3M | $1.5B | 1.3% | $222.42 | +125.38% | 20 qtrssince 2018-Q4 | Decreased 0 |
PRIMECAP MANAGEMENT CO/CA/ manages $118.5B across 331 positions as of Q3 2023. Top holdings: LLY (10.5%), BIIB (3.5%), AMGN (3.3%). Fund DNA: Steady Compounder. HoldingsIntel Score: 3/5.0.
Active quarter - 10 new positions, 7 exits, 59 increased. Top move: INTC (INCREASED, conviction 58). Portfolio: $118.5B across 331 positions.
Top holdings by portfolio weight
Portfolio allocation by GICS sector
Behavioral investing profile
Position Outcomes
Best and worst performing positions by estimated return
Top Winners
Top Losers
Cost basis estimates based on full filing history using quarter-end prices. Actual transaction prices are not disclosed in 13F filings.
Similar Funds
Funds with similar investing DNA
Explore More
Accumulation Streaks
Positions with 2+ consecutive quarters of increases - persistent directional conviction.
Continue exploring
Data sourced from SEC EDGAR 13F filings. Not financial advice. Full disclaimer
Verify source filings on SEC EDGAR